Jyong Biotech Addresses Share Price Volatility After Lock-Up Expiry

Reuters2025-12-19
Jyong Biotech Addresses Share Price Volatility After Lock-Up Expiry

Jyong Biotech Ltd. has issued a statement addressing recent fluctuations in its share price and increased trading volume following the expiry of its lock-up period. The company emphasized that it remains in compliance with its disclosure obligations and is not aware of any material, unpublished price-sensitive information or corporate developments that would explain the recent trading activity. Jyong Biotech cautioned that share price movements can be influenced by various factors beyond its control, such as general market conditions and sector-specific news. The company reiterated its commitment to keeping shareholders informed of all material developments in accordance with applicable laws and regulations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9605106-en) on December 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment